XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net (loss) income $ (777) $ 598
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Net gain (loss) from securities transactions 310 (335)
Purchases of securities (446) (566)
Proceeds from sales of securities 2,084 3,979
Payments to cover securities sold, not yet purchased (3,618) (2,597)
Proceeds from securities sold, not yet purchased 444 1,423
Changes in receivables and payables relating to securities transactions 2,774 15
Changes in derivative assets and liabilities 681 (249)
Gain on disposition of assets, net (3) (2)
Depreciation and amortization 251 249
Loss on deconsolidation of subsidiary 246  
Deferred taxes (88) (18)
Other, net 9 45
Changes in other operating assets and liabilities 110 87
Net cash provided by operating activities 1,977 2,629
Cash flows from investing activities:    
Capital expenditures (131) (154)
Turnaround expenditures (50) (68)
Proceeds from sale of investments   152
Proceeds from disposition of businesses and assets   2
Other, net 25 (1)
Net cash used in investing activities (156) (69)
Cash flows from financing activities:    
Investment segment contributions from non-controlling interests   5
Investment segment distributions to non-controlling interests (1,462)  
Partnership contributions 185 398
Partnership distributions (155) (102)
Dividends and distributions to non-controlling interests in subsidiaries (170) (62)
Repayments of Holding Company senior unsecured notes   (500)
Proceeds from subsidiary borrowings 32 66
Repayments of subsidiary borrowings (48) (122)
Other, net (3) (16)
Net cash used in financing activities (1,621) (333)
Effect of exchange rate changes on cash and cash equivalents and restricted cash and restricted cash equivalents   6
Net increase in cash and cash equivalents and restricted cash and restricted cash equivalents 200 2,233
Cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of period 4,886 4,436
Cash and cash equivalents and restricted cash and restricted cash equivalents, end of period $ 5,086 $ 6,669